CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study

O'Dwyer, M; Henderson, R; Naicker, SD; Cahill, MR; Murphy, P; Mykytiv, V; Quinn, J; McEllistrim, C; Krawczyk, J; Walsh, J; Lenihan, E; Kenny, T; Hernando, A; Hirakata, G; Parker, I; Kinsella, E; Gannon, G; Natoni, A; Lynch, K; Ryan, AE

O'Dwyer, M (reprint author), Univ Hosp Galway, Dept Hematol, Newcastle Rd, Galway H91 NH7V, Ireland.

BLOOD ADVANCES, 2019; 3 (12): 1815

Abstract

Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM). We conducted a phase lb ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索